Time filter

Source Type

Heruc G.A.,University of Adelaide | Heruc G.A.,National Health and Medical Research Council Center for Research Excellence in Translating Nutritional Science to Good Health | Horowitz M.,University of Adelaide | Horowitz M.,National Health and Medical Research Council Center for Research Excellence in Translating Nutritional Science to Good Health | And 9 more authors.
American Journal of Physiology - Endocrinology and Metabolism | Year: 2014

Fat is the most potent stimulus for glucagon-like peptide-1 (GLP-1) secretion. The aims of this study were to determine whether dipeptidyl peptidase IV (DPP-IV) inhibition would enhance plasma active incretin [glucose-dependent insulinotropic polypeptide (GIP), GLP-1] concentrations and modulate the glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to intraduodenal fat infusion. In a double-blind, randomized, placebo-controlled crossover design, 16 healthy lean males received 50 mg vildagliptin (V), or matched placebo (P), before intraduodenal fat infusion (2 kcal/min, 120 min). Blood glucose, plasma insulin, glucagon, active GLP-1, and GIP and peptide YY (PYY)-(3–36) concentrations; resting energy expenditure; and energy intake at a subsequent buffet meal (time = 120–150 min) were quantified. Data are presented as areas under the curve (0–120 min, means ± SE). Vildagliptin decreased glycemia (P: 598 ± 8 vs. V: 573 ± 9 mmol·l−1·min−1, P < 0.05) during intraduodenal lipid. This was associated with increased insulin (P: 15,964 ± 1,193 vs. V: 18,243 ± 1,257 pmol·l−1·min−1, P < 0.05), reduced glucagon (P: 1,008 ± 52 vs. V: 902 ± 46 pmol·l−1·min−1, P < 0.05), enhanced active GLP-1 (P: 294 ± 40 vs. V: 694 ± 78 pmol·l−1·min−1) and GIP (P: 2,748 ± 77 vs. V: 4,256 ± 157 pmol·l−1·min−1), and reduced PYY-(3–36) (P: 9,527 ± 754 vs. V: 4,469 ± 431 pM/min) concentrations compared with placebo (P < 0.05, for all). Vildagliptin increased resting energy expenditure (P: 1,821 ± 54 vs. V: 1,896 ± 65 kcal/day, P < 0.05) without effecting energy intake. Vildagliptin 1) modulates the effects of intraduodenal fat to enhance active GLP-1 and GIP, stimulate insulin, and suppress glucagon, thereby reducing glycemia and 2) increases energy expenditure. These observations suggest that the fat content of a meal, by enhancing GLP-1 and GIP secretion, may contribute to the response to DPP-IV inhibition. © 2014 the American Physiological Society.

Loading National Health and Medical Research Council Center for Research Excellence in Translating Nutritional Science to Good Health collaborators
Loading National Health and Medical Research Council Center for Research Excellence in Translating Nutritional Science to Good Health collaborators